Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571) 272-0500.

Similar presentations


Presentation on theme: "1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571) 272-0500."— Presentation transcript:

1 1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571) 272-0500 jasemine.chambers@uspto.gov

2 2 Topics Today Staffing, Pendency, and Filings Appeal Conferences Restriction Practice Action Plan

3 3 TC 1600 Staffing (9/28/04) GroupsArt UnitsExaminersPhDMS Law School JD Primary PSA 16104561711310267 1620567321907334 16308106643105409 164071116614663512 165047028161927 6 166018022030 TOTAL 2941820793123716438

4 4 TC 1600 Update Pendency FY01 FY02 FY03 FY04 Total Pendency 26.1 25.5 27.8 ? Pendency to First action 12.8 13.2 15.8 ?

5 5 TC 1600 Update Filing Data –FY04appears down –FY03-7.8% (38,613) –FY02+13.8% (41,641) –FY01+11.9%

6 6 TC 1600 Update PCT Filings Constitute 15% of TC 1600 Workload FY04 (as of 9/04) –7,400 Chapter I’s, 4,700 Chapter II’s FY03 –6,000 Chapter I’s, 4,500 Chapter II’s

7 7 Appeal Conferences An appeal conference is mandatory in all cases in which an acceptable appeal brief has been filed and the examiner in charge of the application is going to proceed with the appeal and write an examiner’s answer (MPEP 1208).

8 8 Appeal Conferences The participants in an appeal conference are: –The examiner –The examiner’s SPE –A conferree The conferee is preferably another SPE, SPRE, QAS, or TCPS. However, the conferee may also be a primary examiner having sufficient experience and knowledge to be of assistance in the consideration of the merits of the issues on appeal.

9 9 Appeal Conferences Outcomes: A Notice of Allowance may be issued. An Examiner’s Answer may be issued. A new Office Action may be issued.

10 10 Appeal Conferences Outcomes: FY04 3 rd Qtr –Exmr. Answers 229 (60.1%) –Re-openings 84 (22.0%) –Allowances 61 (16.0%) FY03 –Exmr. Answers 426 (44.6%) –Re-openings 282 (29.5%) –Allowances 237 (24.8%)

11 11 The action plan includes 5 initiatives: 1.Publish Examples Of Claim Sets 2.Emphasis On Rejoinder Practice 3.Examiner Training On Restriction Practice 4.Enhanced Review Of Restriction Requirements 5.Continuous Assessment Restriction Practice Action Plan

12 12 Restriction Practice Action Plan 1.Publish Examples Of Claim Sets –Provide examples that do not present a serious burden on the Office –Provide both applicants and examiners with guidance  We are working on this and anticipate publication within the next several months.

13 13 Restriction Practice Action Plan 2. Emphasis On Rejoinder Practice –Provide a new Rejoinder paragraph –Remind applicants of their options on Rejoinder  This has been implemented.

14 14 Restriction Practice Action Plan 3.Examiner Training On Restriction Practice –Emphasize proper restriction practices Claim groupings and support/formulation of restriction requirements –Provide Art Unit/Workgroup specific examples –Publish materials  Training to examiners delivered at end of August. We will be posting the training materials on the USPTO web site.

15 15 Restriction Practice Action Plan 3.Examiner Training On Restriction Practice – cont.  Includes:  Basic Restriction Requirements  Linking Claims  Markush Practice  Rejoinder Opportunities

16 16 Restriction Practice Action Plan 4.Enhanced Review Of Restriction Requirements –Review Art Units with high number of restrictions and indications of inconsistent requirements –Includes reviewing restrictions in 2 nd and subsequent actions  This has been implemented.

17 17 Restriction Practice Action Plan 5.Continuous Assessment –Collect data from reviews and samplings –Survey customers on impact of action plan  We are currently collecting data from reviews.

18 18 Thank You Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571) 272-0500 jasemine.chambers@uspto.gov


Download ppt "1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571) 272-0500."

Similar presentations


Ads by Google